Loading...
•
Dec 31, 2024
TG Therapeutics Q4 2024 Earnings Report
TG Therapeutics reported strong revenue growth in Q4 2024, driven by the success of BRIUMVI sales.
Key Takeaways
TG Therapeutics delivered a strong Q4 2024, with significant revenue growth fueled by the continued adoption of BRIUMVI. The company achieved profitability with a net income of $23.3 million, compared to a net loss in the prior year.
Q4 revenue increased to $108.2 million, driven by BRIUMVI sales.
Net income reached $23.3 million, compared to a net loss of $14.4 million in Q4 2023.
Operating income turned positive at $29.9 million, reflecting strong performance.
Cash position increased to $311 million, supporting future growth initiatives.
TG Therapeutics
TG Therapeutics
Forward Guidance
TG Therapeutics expects continued revenue growth in 2025, with a focus on expanding BRIUMVI's market reach and advancing its development pipeline.
Positive Outlook
- Targeting $540 million in total global revenue for FY 2025.
- Expecting $525 million in BRIUMVI US net product revenue.
- Advancing development of subcutaneous BRIUMVI.
- Expanding BRIUMVI’s presence in Europe through Neuraxpharm partnership.
- Strong cash position of $311 million supports future growth.
Challenges Ahead
- Increased R&D spending for pipeline expansion.
- Higher SG&A expenses due to commercialization efforts.
- Regulatory challenges may impact international expansion.
- Market competition in the MS treatment space remains high.
- Potential pricing pressures could affect future revenue growth.